Barrett's Esophagus Clinical Trials
A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 349 clinical trials
[18F]FLUOROPROPYL-TRIMETHOPRIM (F-TMP) PET/CT IMAGING TO EVALUATE BIODISTRIBUTION AND KINETICS IN HUMAN SUBJECTS
Patients with known or suspected bacterial infection at the time screening are eligible for this study. Patients may participate in this study if they are at least 18 years of age, and most participants will be receiving care at the clinical practices of the University of Pennsylvania. Up to 20 …
The Effect of Potassium Nitrate [KNO3] on Exercise Capacity in Heart Failure Patients.
This study will test whether Potassium Nitrate (KNO3) will improve how people with HFpEF [Diastolic Heart Failure] can exercise. In HFpEF, patients are limited in their ability to do all the things they want to do, and exercise as much as they would like, due to becoming tired and short …
Weight Loss
Weight loss can result from a decrease in body fluid, muscle mass, or fat. A decrease in body fluid can come from medications, fluid loss, lack of fluid intake, or illnesses such as diabetes. A decrease in body fat can be intentionally caused by exercise and dieting, such as for overweight or obesity.
NASA Specialized Center of Research (NSCOR) for Evaluating Risk Factors and Biomarkers for Adaptation and Resilience to Spaceflight: Emotional Valence and Social Processes in ICC/ICE Environments
NASAs vision for successful long-duration exploration missions depends on optimizing human performance, adaptability, and resiliency to reduce individual and crew behavioral risks. To date, the major emphasis in optimizing astronauts for their tolerance to prolonged spaceflight has involved human health and performance countermeasures as well as technologies and tools to …
A PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF NIRAPARIB AND TUMOR-TREATING FIELDS IN RECURRENT GLIOBLASTOMA
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and is near uniformly fatal. Only three treatments have been approved by the US FDA for GBM in the past 2 decades: temozolomide, bevacizumab, and, most recently, tumor-treating fields (TTFields). TTFields represents a novel anti-cancer modality that creates …
Trial to Optimize Patients Selection for Endovascular Treatment in Acute Ischemic Stroke
Stroke can occur when a clot stops the flow of the blood in one of the arteries supplying the brain. This type of stroke, called ischemic stroke, can be treated alone or in a combination of drugs to dissolve the clot, devices to remove the clot (mechanical thrombectomy) or use …
Substudy: Understanding COVID-19 vaccine responses in the setting of immunotherapy
Since its emergence, SARS-Cov2 has rapidly and widely spread across the globe due to lack of prior protective immunity in the human species. With widespread mitigation measures, all efforts focused on generating effective vaccination strategies that will provide herd immunity and protect the most vulnerable populations. However, there is very …
Detection of cell-free circulating tumor DNA in patients with glioblastma undergoing treatment with first-line chemoradiotherapy
Glioblastoma (GBM) is the most common primary brain tumor in adults and is uniformly fatal. During standard adjuvant treatment for GBM following initial surgical resection of the tumor, patients are treated with a combination of radiation and chemotherapy. During and after this adjuvant treatment, patients are monitored for disease progression …
Testing Novel Pharmacogenetic and Adherence Optimization Treatments to Improve the Effectiveness of Smoking Cessation Treatments for Smokers with HIV
The research study is being conducted to examine the effects of personalized smoking cessation medication treatment in order to help people with HIV/AIDS to quit smoking. During the study, participants will take either varenicline (brand name Chantix®) or use the nicotine patch, and they will receive smoking cessation therapy with …
Alzheimers Disease Neuroimaging Initiative 3 (ADNI3)
Since its launch in 2004, the overarching aim of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI1, ADNI-GO, and ADNI2 studies that have been combined public/private collaborations between academia and industry to determine the …
